Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

Table 2 Univariate Cox Regression Models of Relapse-free Survival and Overall Survival

	No of events/No of patients	Median Relapse- free Survival (months)	P value	No of events/No of patients	Median Overall Survival (months)	P value
AG 49
A/A	71/132	59.56	0.55	47/132	NR*	0.55
A/G	70/128	46.42		47/128	84.20
G/G	17/26	35.35		11/26	63.38
CT 318
C/C	122/229	54.67	0.52	82/229	NR	0.36
C/T	34/55	47.67		21/55	NR
T/T	2/2	37.35		2/2	51.02
CT 60
A/A	34/65	58.87	0.68	23/65	NR	0.64
A/G	85/151	47.67		54/151	84.20
G/G	39/70	53.22		28/70	76.68
JO 27
C/C	37/73	58.87	0.60	26/73	NR	0.76
T/C	84/153	54.67		54/153	84.20
T/T	37/60	37.29		25/60	76.68
JO 30
A/A	37/72	56.71	0.65	27/72	NR	0.74
G/A	83/151	54.80		52/151	NR
G/G	38/63	37.29		26/63	76.68
JO 31
T/T	35/71	72.08	0.37	23/71	NR	0.50
G/T	85/151	47.67		56/151	80.69
G/G	38/64	39.43		26/64	76.68

ISSN: 1479-5876